Inactive
Notice ID:FDA-RFQ-2021-1238225
FDA has a requirement to procure “Pharmacy Supplies”-to be Sole Sourced to the Program Support Center., under Request for Quote FDA-RFQ-2021-1238225. The Division of Applied Regulatory Science (DARS) ...
FDA has a requirement to procure “Pharmacy Supplies”-to be Sole Sourced to the Program Support Center., under Request for Quote FDA-RFQ-2021-1238225. The Division of Applied Regulatory Science (DARS) OCP/OTS/CDER is evaluating in vitro and in vivo pharmacokinetic assessment of biosimilarity and evaluating models of toxicity assessment for new drug classes. As part of this process DARS needs to acquire these pharmacy drugs to evaluate their parameters: i. Peg-interferon beta - (Plegridy, 125ug syringe, pk of 2 pens); NDC/NSN = 64406-011-01 ii. Interferon beta - (Avonex, 4 - 30ug pre-filled syringes); NDC/NSN = 59627-333-04 iii. Pegloticase (Krystexxa, 8 mg/ml, 1ml vial); NDC/NSN = 75987-080-10 iv. Alirocumab (Praluent, 75 mg/ml, 1ml syringe); NDC/NSN = 0024-5901-01 v. Reslizumab (Cinqair, 10 mg/ml, 10ml vial); NDC/NSN = 59310-610-31. See attached notice,